Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries

Blood

Volumn 97, Issue 6, 2001, Pages 1776-1786

  La Rosa, Corinna ^b   Krishnan, Radhika ^b   Markel, Susan ^b   Schneck, Jonathan P ^b   Houghten, Richard ^b   Pinilla, Clemencia ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; COMBINATORIAL LIBRARY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0035869405     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1776     Document Type: Article

References (59)

1. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties
2. (209·217)-reactive T cells in patients following vaccination with a peptide modified at an HLA A-A2.1 anchor residue
3. Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries
4. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries
5. The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells
6. Mixture-based synthetic combinatorial libraries
7. Prophylaxis and treatment of CMV infections in transplantation
8. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome
9. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine: The zidovudine epidemiology study group
10. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo
11. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs
12. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus [in process citation]
13. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
14. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: Dependence on HLA class II restricted T(H) response
15. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection, I: Induction of a primary cytotoxic T lymphocyte response in humans
16. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans
17. Development of an in vitro stimulation protocol to measure CMV specific CTL activity using HLA-restricted CTL epitopes
18. T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: Studies with cyclosporin A
19. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2
20. The human CTL response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T cell receptor usage of pp65-specific CTL
21. Targeting p53 as a general tumor antigen
22. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients
23. Identification of peptide sequences that potentially trigger HLA- A2.1-restricted cytotoxic T lymphocytes
24. Molecular analysis of T cell repertoire in bone marrow transplant recipients: Evidence for oligoclonal T cell expansion in GVHD
25. Methods for determining expression and oligoclonality of TCRs in GVHD lesions from allogeneic BMT recipients
26. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors
27. T-cell epitope mapping by flow cytometry
28. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants
29. Peptide binding to HLA-DR1: A peptide with most residues substituted to alanine retains MHC binding
30. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules
31. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1 (27-35) peptide: Implications for peptide vaccines
32. Exploring immunological specificity using synthetic peptide combinatorial libraries
33. Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL
34. MHC ligands and peptide motifs: First listing
35. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
36. Definition of specific peptide motifs for four major HLA-A alleles
37. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2
38. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
39. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines
40. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy
41. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: Biochemical probes for analysis and modulation of immune responses
42. Peptide-induced antiviral protection by cytotoxic T cells
43. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination
44. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis
45. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
46. Induction of an MHC complex Class I-restricted CTL response to a highly conserved region of HIV type 1 in seronegative humans immunized with a candidate HIV-1 vaccine
47. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants
48. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein
49. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
50. Peptides naturally presented by MHC class I molecules
51. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
52. CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo
53. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides
54. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants
55. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA A*0201-binding residues
56. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology
57. Immunogenicity, I: Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands
58. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
59. 495-503 epitope sequence presented by the HLA A*020l allele among human cytomegalovirus isolates